In this segment from Tuesday's Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass look at Merck (MRK 0.24%), and why its pipeline is one investors should be excited about today.
Amazingly, Merck looks as though it will be the first to market with its PD1 immuno-oncology drug 3475, beating the seeming favorite Bristol-Myers Squibb's (BMY -0.18%)nivolumab. David tells investors why he's excited about this coming megablockbuster and its potential for off-label use, as well as which key trials for the drug investors will want to watch for this year.
